Role of MIB1 in Predicting Survival in Patients with Glioblastomas |
| |
Authors: | Shaye I Moskowitz Tao Jin Richard A Prayson |
| |
Institution: | (1) Department of Neurosurgery, The Cleveland Clinic Foundation, Cleveland, OH, USA;(2) Department of Biostatistics, The Cleveland Clinic Foundation, Cleveland, OH, USA;(3) Department of Anatomic Pathology, The Cleveland Clinic Foundation, 9500 Euclid Anatomic, L-25, 44195 Cleveland, OH, USA |
| |
Abstract: | Summary Background: Histologic immunomarkers of cell cycle proteins have been utilized for prognosis in high-grade astrocytic tumors. One such
marker, MIB1, an antibody immunoreactive throughout the cell cycle, is predictive of more aggressive disease and poorer prognosis
in astrocytomas. An independent role of MIB1 analysis for survival prediction and clinical management within histologic grades
has not been clearly proven.
Methods: This study retrospectively evaluated MIB1 reactivity in tissue samples from 116 patients with glioblastomas on initial medical
presentation. Clinical variables considered included gender, age, Karnofsky Performance Scores (KPS), extent of surgical resection,
adjuvant radiation and survival.
Results: Univariate and multivariate analyses were used to correlate these variables with MIB1 staining. MIB1 staining does not predict
overall survival or response to adjuvant therapy as an independent risk factor.
Conclusion: MIB1 labeling does not predict patient survival as an independent variable and does not predict response to additional therapies.
Patient survival with glioblastoma was predicted by KPS, age, extent of resection and use of adjuvant radiotherapy. |
| |
Keywords: | glioblastomas MIB1 predictor radiotherapy staining survival |
本文献已被 PubMed SpringerLink 等数据库收录! |
|